ALK and neoplasm: However, our study has limitations that need to be addressed in future research, including the uneven distribution of patients across stages (with 59% of patients at Stage I), the lack of information on treatment regimens, and the genetically diverse population of patients without EGFR mutations, which may include tumours driven by other oncogenes such as ALK, RAS and ROS1.3